Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial

BACKGROUND: The phase 3 RECORD-1 trial (NCT00410124) established the efficacy and safety of everolimus in patients with metastatic renal cell carcinoma (mRCC) who progress on sunitinib or sorafenib. In RECORD-1, patients received 10 mg everolimus daily, with dose reduction to 5 mg daily allowed for...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein, Andrew, Wang, Wenping, Carter, Alison A, Chiparus, Ovidiu, Hollaender, Norbert, Kim, Hyewon, Motzer, Robert J, Sarr, Celine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495014/
https://www.ncbi.nlm.nih.gov/pubmed/22824201
http://dx.doi.org/10.1186/1471-2407-12-311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495014/
https://www.ncbi.nlm.nih.gov/pubmed/22824201
http://dx.doi.org/10.1186/1471-2407-12-311

Ejemplares similares